US 12,258,360 B2
Compositions and methods for treatment of anticancer-drug resistant cancers
Wenge Zhu, Germantown, MD (US); Jing Li, Arlington, VA (US); and Yiliang Li, Tianjin (CN)
Assigned to The George Washington University, Washington, DC (US)
Filed by THE GEORGE WASHINGTON UNIVERSITY, Washington, DC (US)
Filed on Sep. 14, 2022, as Appl. No. 17/944,506.
Application 17/944,506 is a continuation of application No. PCT/US2021/026164, filed on Apr. 7, 2021.
Claims priority of application No. 202010271412.4 (CN), filed on Apr. 7, 2020.
Prior Publication US 2023/0129381 A1, Apr. 27, 2023
Int. Cl. C07F 5/02 (2006.01); A61K 31/69 (2006.01); A61P 35/00 (2006.01); C07D 311/02 (2006.01)
CPC C07F 5/025 (2013.01) [A61K 31/69 (2013.01); A61P 35/00 (2018.01); C07D 311/02 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A compound represented by formula I or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein, R1 is independently mono-or poly-substituted with hydrogen, trifluoromethyl, trifluoromethoxy, nitro, cyano, halogen, C1-C10 alkyl, or —OR2,
wherein R2 is independently selected from hydrogen or C1-C10 alkyl.